Sector
PharmaceuticalsOpen
₹12,000Prev. Close
₹11,962Turnover(Lac.)
₹4,049.04Day's High
₹12,199Day's Low
₹11,91652 Week's High
₹18,10052 Week's Low
₹7,157.95Book Value
₹1,196.47Face Value
₹10Mkt Cap (₹ Cr.)
15,549.83P/E
76.96EPS
157.47Divi. Yield
0.1The transaction takes place against the backdrop of a more than 9% reduction in the stock's value during the previous week.
However, it is unclear whether the Hyderabad-based company will be Cobenfy's exclusive supplier.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 12.9 | 12.9 | 12.9 | 12.9 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,263.64 | 975.46 | 822.67 | 768.98 |
Net Worth | 1,276.54 | 988.36 | 835.57 | 781.88 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Revenue | 951.07 | 936.91 | 762.71 | 666.82 |
yoy growth (%) | 1.51 | 22.83 | 14.37 | 26.43 |
Raw materials | -422.13 | -438.41 | -380.19 | -366.24 |
As % of sales | 44.38 | 46.79 | 49.84 | 54.92 |
Employee costs | -175.75 | -144.02 | -118.48 | -104.47 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Profit before tax | 81.73 | 104.96 | 52.49 | 19.83 |
Depreciation | -49.03 | -39.67 | -31.27 | -25.86 |
Tax paid | -18.2 | -24.66 | -36.61 | -3.69 |
Working capital | 83.75 | -74.79 | 43.14 | 0.41 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 1.51 | 22.83 | 14.37 | 26.43 |
Op profit growth | -2.9 | 44.33 | 75.33 | 15.66 |
EBIT growth | -22.48 | 65.87 | 108.65 | 9.35 |
Net profit growth | -20.87 | 405.63 | -1.63 | 36.71 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 1,476.84 | 1,558.58 | 1,191.2 | 951.08 | 936.91 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,476.84 | 1,558.58 | 1,191.2 | 951.08 | 936.91 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 96.91 | 12.54 | 9.75 | 2.08 | 16.1 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
D R Rao
Non Executive Director
Christopher M Cimarusti
Vice Chairman & CEO
D Sucheth Rao
Vice Chairman & M.D.
D Saharsh Rao
Company Sec. & Compli. Officer
Sarada Bhamidipati
Independent Director
Homi Rustam Khusrokhan
Independent Director
Prasad R Menon
Independent Director
Sugata Sircar
Independent Director
Pallavi Joshi Bakhru
11 Th Floor Phoenix IVY Buildi,
Plot No 573A-III Road No 82,
Telangana - 500035
Tel: 91-40-30211600
Website: http://www.neulandlabs.com
Email: [email protected]
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: [email protected]
Summary
Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao. The Company is engaged in manufacturing and selling of bulk drugs such as salbutamol sulphate, ...
Read More
Reports by Neuland Laboratories Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.